Close Menu

This story has been updated to clarify comments made by Blueprint Medicines' Chrissy Ross during a call with investors. 

NEW YORK – Roche said on Tuesday that it will pay Blueprint Medicines $775 million for certain rights to its RET inhibitor pralsetinib under a collaboration agreement between the companies.  

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.